A new weight loss drug, ecnoglutide, has successfully completed its largest clinical trial, with nearly 90% of participants losing at least 5% of their body weight. In the Phase III SLIMMER trial, researchers found that those taking ecnoglutide lost an average of 9-13% of their body weight after 40 weeks, while those on a placebo experienced little to no weight change. Side effects were minimal, with mild digestive upsets being the most common.
The results strengthen ecnoglutide’s case for US Food and Drug Administration approval, particularly given its favorable safety profile and potential to produce continued weight loss beyond the trial period. Ecnoglutide is a novel GLP-1 receptor agonist that may be more effective in targeting weight loss and insulin secretion due to its single pathway activation within cells.
Source: https://newatlas.com/disease/obesity/weight-loss-drug-trial